Related Experiment Video
Updated: Jul 10, 2025
14:04
Viral Nanoparticles for In vivo Tumor Imaging
Published on: November 16, 2012
17.3K
Progress in oncolytic viruses modified with nanomaterials for intravenous application
Liting Chen1,2,3, Zhijun Ma4, Chen Xu1,2,3
1Department of Surgical Oncology and General Surgery, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Affiliated Hospital of China Medical University, Shenyang 110001, China.
Cancer Biology & Medicine
|November 27, 2023
Summary
Oncolytic virus (OV) therapy uses modified viruses to target cancer cells. Nanomaterial modifications enhance OV safety and efficacy for intravenous delivery, overcoming current clinical limitations.
Area of Science:
- Oncology
- Immunotherapy
- Nanomedicine
- Virology
Background:
- Oncolytic virus (OV) therapy is a promising cancer immunotherapy that utilizes viruses to selectively destroy tumor cells and stimulate anti-tumor immune responses.
- Current clinical applications of OVs are restricted to intratumoral injections due to high immunogenicity and rapid immune clearance during systemic circulation.
- Nanomaterial modification of OVs offers a strategy to improve their safety and enable intravenous administration.
Purpose of the Study:
- To review recent advances in using nanomaterials to modify OVs for enhanced cancer therapy.
- To summarize preclinical findings on liposome, polymer, and albumin-modified OVs.
- To discuss challenges and future directions for translating nanomodified OVs from basic research to clinical practice.
Main Methods:
- Review of preclinical studies investigating nanomaterial-modified oncolytic viruses.
- Focus on modifications using liposomes, polymers, and albumin for improved OV delivery and safety.
- Analysis of strategies aimed at overcoming limitations of traditional OV therapy.
Main Results:
- Nanomaterial modifications, including liposomes, polymers, and albumin, have shown potential in decreasing OV virulence and enhancing safety for systemic delivery.
- Preclinical studies demonstrate improved biodistribution and tumor targeting of nanomodified OVs.
- These modifications facilitate intravenous injection, expanding the therapeutic potential of OVs.
Conclusions:
- Nanomaterial engineering represents a key strategy to overcome the clinical limitations of oncolytic virus therapy.
- Further research is needed to address challenges in preclinical-to-clinical translation for nanomodified OVs.
- Successful translation could significantly broaden the application of OV-based cancer immunotherapy.
